Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22393430 | 0.89 | CYP3A4 (0.44) | BTN3A1RIPK1CYP3A4CYP2C9DOT1L | |
| SCHEMBL22393558 | 0.89 | CYP3A4 (0.44) | BTN3A1RIPK1CYP3A4CYP2C9DOT1L | |
| SCHEMBL24058411 | 0.89 | DOT1L (0.32) | RIPK1DOT1LPOLRMT | |
| SCHEMBL22355507 | 0.89 | DOT1L (0.32) | RIPK1DOT1LPOLRMT | |
| SCHEMBL18666884 | 0.89 | DOT1L (0.32) | RIPK1DOT1LPOLRMT | |
| SCHEMBL19504133 | 0.89 | DOT1L (0.32) | RIPK1DOT1LPOLRMT | |
| SCHEMBL24699947 | 0.88 | BTN3A1 (0.34) | BTN3A1RIPK1CYP3A4CYP2C9DOT1L | |
| SCHEMBL24700006 | 0.88 | BTN3A1 (0.34) | BTN3A1RIPK1CYP3A4CYP2C9DOT1L | |
| SCHEMBL23047652 | 0.87 | RIPK1 (0.33) | BTN3A1RIPK1CYP3A4CYP2C9DOT1L | |
| SCHEMBL24158211 | 0.87 | DOT1L (0.34) | RIPK1DOT1LPOLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |